DESFERAL (deferoxamine mesylate)
Development Insights
Details
- Status
- Discontinued
- First Approved
- 1968-04-01
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
DESFERAL Approval History
What DESFERAL Treats
2 FDA approvalsOriginally approved for its first indication in 1968 . Covers 2 distinct patient populations.
- Other (2)
Other
(2 approvals)- • Approved indication (Apr 1968) Priority
- • Approved indication (Jun 1979)
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06763055 INTERACT5 | ACT-GLOBAL_ICH_01 | Ph 3 | recruiting | The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL |
| NCT02175225 results posted | 2012P000005 U01NS074425 | Ph 2 | completed | Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial |
| NCT00598572 DFO In ICH | 2007P000288 1R01NS057127-01A1 | Ph 1 | completed | Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DESFERAL FDA Label Details
Track DESFERAL with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment